MEDG Medgenics(Regs)

    Medgenics, Inc.
                         ('Medgenics' or the 'Company')
                                        
                          Issue of options to Director
                                        
                                                                 4 December 2008

On  1 December 2008 the Company issued Lord Leonard Steinberg, a director of the
Company,  options over 1,711,319 Common Shares (the "Options")  in  compensation
for his services as a director of the Company.  These Options are exercisable at
a  price of 2.875 pence per Common Share and vest in three equal tranches  on  1
February  2009,  1 February 2010 and 1 February 2011 and expire  on  1  February
2011.   Following  the  issue  of the Options, Lord  Leonard  Steinberg  is  now
interested  in 22,938,428 Common Shares (14,484,725 Common Shares,  warrants  to
purchase  6,742,384  Common Shares and options over a further  1,711,319  Common
Shares).

For further information, contact:

Medgenics, Inc.                                               Phone: +972 4 902 8900
Dr. Andrew L. Pearlman                     

Grayling Global (Financial PR, UK)                            Phone: +44 207 255 5406
Jonathan Shillington                                          jonathan.shillington@uk.grayling.com
Alistair Scott                             

Blomfield Corporate Finance Limited (Nominated Adviser)       Phone: +44 207 489 4500
                        
James Pinner
Alan MacKenzie

SVS Securities plc (Broker)                                   Phone: +44 207 638 5600
Peter Manfield                             
Ian Callaway

United States contacts:                    
                                           
Grayling Global (Investor Relations)                          Phone: +1 646 284 8472
Leslie Wolf-Creutzfeldt                                       lwolf-creutzfeldt@hfgcg.com
                                           
                                           
Grayling Global (Media Relations)                             Phone: +1 646 284 9455
Ivette Almeida                                                ialmeida@hfgcg.com
                                           

NOTES TO EDITORS:

Medgenics,  Inc.  is a clinical-stage biopharmaceutical company  developing  its
unique  tissue-based  Biopump  platform technology to  provide  sustained-action
protein therapy for the treatment of a range of chronic diseases.

Medgenics currently has two products in development based on this technology:

*    EPODURE - producing erythropoietin (EPO) to treat anemia
*    INFRADURE - producing interferon-alpha (IFN-a) to treat hepatitis C

The  Company  has  demonstrated  proof of principle  of  the  Biopump  treatment
procedure in a clinical trial using a short-acting version of EPODURE in  anemic
subjects.  The  Company announced positive initial results  in  its  Phase  I/II
clinical  trial for its long-acting version of EPODURE, designed to produce  and
deliver  a  therapeutic dose of EPO steadily for three to six  months  or  more,
which  commenced  in August 2008. The Company plans to follow  with  a  clinical
trial of INFRADURE in 2009.

Medgenics  intends to develop its innovative products and bring them  to  market
via  multiple  strategic partnerships with major pharmaceutical  and/or  medical
device companies, starting with EPODURE and INFRADURE.

Beyond these, Medgenics plans to develop and/or out-license a pipeline of future
Biopump  products targeting the large and rapidly growing global protein therapy
market, which is forecast to reach US $87 billion by 2010. Other potential areas
include multiple sclerosis (interferon-a), haemophilia (Factor XIII), paediatric
growth hormone deficiency (human growth hormone) and diabetes (insulin).

Founded in 2000, Medgenics is a US-incorporated company with major operations in
Misgav, Israel. Medgenics was admitted to AIM in December 2007 (AIM: MEDG).

www.medgenics.com

CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
This  release contains forward-looking statements, which include all  statements
other  than statements of historical fact, including (without limitation)  those
regarding  the  Company's  financial  position,  business  strategy,  plans  and
objectives  of  management  for future operations. These  statements  relate  to
future   events,   prospects,   developments  and  strategies.   Forward-looking
statements  are sometimes identified by their use of the terms and phrases  such
as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning,
"expect," "believe," "will," "will likely," "should," "could," "would," "may" or
the  negative of such terms and other comparable terminology. All such  forward-
looking  statements are based on current expectations and are subject  to  risks
and  uncertainties. Should any of these risks or uncertainties  materialize,  or
should  any  of  the Company's assumptions prove incorrect, actual  results  may
differ  materially from those included within these forward-looking  statements.
Accordingly,  no  undue  reliance  should be  placed  on  these  forward-looking
statements,  which  speak  only  as  of the date  made.  The  Company  expressly
disclaims  any obligation or undertaking to disseminate any updates or revisions
to  any forward-looking statements contained herein to reflect any change in the
Company's  expectations with regard thereto or any change in events,  conditions
or  circumstances on which any such statements are based. As a result  of  these
factors,  the  events described in the forward-looking statements  contained  in
this release may not occur.

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024